Medy-Tox Inc. (KOSDAQ:086900)

South Korea flag South Korea · Delayed Price · Currency is KRW
109,200
+1,700 (1.58%)
Apr 29, 2026, 1:40 PM KST
-33.21%
Market Cap 704.68B
Revenue (ttm) 247.29B
Net Income (ttm) 15.62B
Shares Out 6.56M
EPS (ttm) 2,371.01
PE Ratio 45.34
Forward PE 27.99
Dividend 1,200.00 (1.11%)
Ex-Dividend Date Sep 29, 2025
Volume 29,330
Average Volume 34,279
Open 109,000
Previous Close 107,500
Day's Range 107,900 - 110,300
52-Week Range 96,400 - 182,700
Beta 0.49
RSI 51.58
Earnings Date May 15, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 718
Stock Exchange KOSDAQ
Ticker Symbol 086900
Full Company Profile

Financial Performance

In 2025, Medy-Tox's revenue was 247.29 billion, an increase of 8.17% compared to the previous year's 228.62 billion. Earnings were 15.62 billion, a decrease of -2.26%.

Financial Statements

News

There is no news available yet.